One shot of HPV vaccine?

　　One shot of HPV vaccine?

　　Yangcheng Evening News reporter Chen Zeyun

　　Intern Wang Yi

　　Recently, the HPV vaccine has reached the top of the hot search list.

The World Health Organization announced that the organization convened an immunization strategy expert group meeting from April 4 to 7 to review the evidence for single-dose human papillomavirus (HPV) vaccination and concluded that single-dose HPV vaccination Vaccination regimens were effective in preventing cervical cancer caused by persistent HPV infection and were comparable to two- or three-dose regimens.

　　In recent years, the problem of "hard to get a single shot" of the HPV vaccine has become very prominent.

Judging from the immunization procedures of the HPV vaccines that have been approved and marketed, basically two or three doses are used.

A single-dose vaccination program may greatly reduce the cost and difficulty of vaccination implementation, thereby increasing HPV vaccination coverage.

Wantai Biological announced that it will continue to sell according to the currently approved doses before the national policy changes.

　　WHO recommends only one dose

　　On April 11, the World Health Organization announced on its official website that the organization held an expert group meeting on immunization strategies from April 4 to 7 to review the evidence for HPV vaccination.

The expert group considered that only 1 dose of HPV vaccine can produce the same immune effect as 2-3 doses, and can effectively prevent cervical cancer caused by HPV infection.

　　The Strategic Expert Group on Immunization recommends the following immunization schedule: 1 or 2 doses for women aged 9-14 years (the highest priority group); 1 or 2 doses for women aged 15-20 years; women over 21 years of age 2 doses (6 months apart).

Immunocompromised individuals, including those with HIV, should receive 3 doses of the vaccine if feasible, and at least 2 doses.

　　It is worth noting that the World Health Organization has also emphasized that the current data on the efficacy of single-dose efficacy is still limited, and the organization will hold a stakeholder consultation on these important policy changes before revising the position paper on HPV vaccines. Meeting.

　　Company: still sell according to the current dosage

　　Statistics show that in 2021, global HPV vaccine sales will total about $6.3 billion.

Up to now, there are 5 HPV vaccines approved and marketed in the world, namely GlaxoSmithKline's bivalent HPV vaccine, Merck's quadrivalent HPV and nine-valent HPV vaccine, Wantai Bio's bivalent HPV vaccine and Watson Bio II The latter two companies are Chinese companies.

　　In my country, these five vaccines have all been approved for marketing.

Judging from the immunization procedures of the approved HPV vaccines, basically two or three doses of vaccination are used, and there is no single-dose vaccination yet.

From the pricing point of view, among the products that have been listed, the price of each dose is more than 300 yuan, and even more than 1,000 yuan.

　　Affected by the above news, A-share related stocks have fallen sharply in recent days.

When will the "one-shot era" of HPV vaccine come?

Wantai Bio responded on the 14th that the company's products are vaccine products approved and registered by the State Food and Drug Administration under a large number of clinical studies and data demonstrations. doses), and competing products Merck and GlaxoSmithKline are all 3 doses.

Under the current national drug administration policy, such as changes in vaccination doses, a series of clinical, data support and registration change procedures need to be performed, which will take a certain amount of time and will not have a significant impact on the company's operating performance in the short term.

Before the national policy changes, the company will continue to sell according to the currently approved doses, but in the future, it is not ruled out that the WHO and the Chinese government will actively promote the 1-dose or 2-dose vaccination program.

　　Vaccination rates need to increase

　　In fact, the World Health Organization's recommendations are mainly based on the purpose of increasing HPV vaccine coverage.

Data show that as of 2019, the global HPV vaccination rate for girls under the age of 15 has only reached about 15%, far below the WHO's goal of 90% coverage by 2030 for the Cervical Cancer Elimination Initiative.

Due to price and other reasons, it is difficult for many countries to achieve high coverage of two-dose HPV vaccination, especially in recent years, the insufficient supply of HPV vaccine has also hindered the widespread coverage and promotion of the vaccine.

　　The minutes of the meeting of the immunization strategy expert group pointed out that a single dose of vaccination costs less, occupies less resources, and is easier to manage. challenges, and the savings in health funding and human resources can be used for other health priorities.

　　In my country, there are about 292 million women aged 20-45 in this age-appropriate vaccination group. Data from the China Business Data Research Institute shows that from the perspective of batch issuance, the total batch issuance of HPV vaccines in my country has shown a significant upward trend in 2017. -In 2021, the cumulative number of HPV vaccines issued in my country will increase from 1.46 million to 67.39 million, with a compound annual growth rate of 160.65%.

In 2021, a total of 181 batches of bivalent HPV vaccines will be issued in batches, a year-on-year increase of 269%; 44 batches of nine-valent HPV vaccines will be issued in batches, an increase of 83% year-on-year.

Based on this rough calculation, the HPV vaccine gap is still huge.

　　Wantai Biology stated in the announcement that it will actively respond to the WHO and the National Cervical Cancer Elimination Action Plan, and provide more products to the society to meet the market supply by increasing production capacity. In 2021, the company's production capacity has reached 30 million pieces.

　　The National Health and Health Commission recently issued the "National Health and Health Commission's Implementation Plan for the Implementation of the 2021-2030 Outline for the Development of Chinese Women and Children", which proposes that by 2030, the screening rate of cervical cancer among women of appropriate age will reach more than 70%.

Popularize women's "two cancers" prevention and control knowledge, and encourage areas where conditions permit to gradually carry out free HPV vaccination for school-age girls.

In the past two or three years, many cities, including Guangzhou, have begun to carry out free or subsidized HPV vaccine vaccination for school-age women.